EpitogenX

EpitogenX is a biotechnology company spun out from the University of Aberdeen that specializes in a proprietary epitope display platform called EpitoGen. The technology enables the precise display of specific protein regions to improve the sensitivity and specificity of diagnostic tests and the efficacy of vaccines. Initially focused on developing next-generation COVID-19 diagnostics, the company's tests can differentiate between vaccine-induced and infection-induced antibodies. EpitogenX is expanding its pipeline to address other infectious diseases and autoimmune conditions by leveraging its scalable protein engineering approach. The company aims to provide high-throughput, cost-effective solutions for global health monitoring and personalized medicine.